In patients with a baseline blood eosinophil cutoff of at least @ cells per L , exacerbation rates in the benralizumab @ mg group ( n = @ ) and @ mg group ( n = @ ) were lower than in the placebo group ( n = @ ; @ vs @ , reduction @ % , @ % CI @ to @ , p = @ for @ mg dose ; @ vs @ , difference @ % , @ % CI @ to @ , p = @ for @ mg dose ) .